A selective growth-inhibitory effect of Mithramycin A has been observed in FLCN-deficient tumor cells as well [41],which are characterized by activated wild-type TFE3 [20], suggesting that TFE3-driven tumor cells may be specifically sensitive to this drug. Here, TFE3 is linked to neoplasm.